Suven Pharmaceuticals’ shares surged 14% to Rs 1,328.20 on the BSE during Thursday’s trade. This rise is due to heavy trading volumes and positive business outlook expectations. The stock rebounded 43% from its January low of Rs 929 and is near its record high of Rs 1,359.
Analysts credit this rise to Suven’s strong performance in the Pharma CDMO segment, which grew 101% year-on-year. In Q3FY25, Suven’s revenue increased 40% to Rs 676.4 crore. The company reported gross margins at 71.5% and adjusted EBITDA margins at 38.7%. Suven’s profit after tax (PAT) doubled to Rs 168.1 crore from Rs 83.8 crore in Q3FY24.
Experts are optimistic about Suven Pharma’s future. The company’s solid financial performance and growth in the Pharma CDMO segment support this view. Suven’s strategic initiatives and strong market position are expected to drive continued growth and shareholder value.
